All In Biotech

Drug Trial Radar · NCT04772079

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Mar 23, 2021

Primary completion

Jan 1, 2029

Study completion Sep 8, 2033

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Feb 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort. Part A will evaluate the drug levels of BMS-986165 to enable selection of 2 dose levels to be studied in Part B. Part B will assess the efficacy and safety of two dose levels in children and adolescent participants with moderate to severe plaque psoriasis. The 5-year long-term extension (LTE) period will observe the long-term safety and tolerability of deucravacitinib in children and adolescent participants with psoriasis who have completed Parts A or B of the study.

Conditions

  • Plaque Psoriasis

Interventions

  • DeucravacitinibDrug

    Specified dose on specified days

  • Placebo matching deucravacitinibOther

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Observed average concentration at steady state for deucravacitinib at Week 2Time frame: Week 2
  2. Maximum observed plasma concentration at steady state for deucravacitinib at Week 2Time frame: Week 2
  3. Trough observed plasma concentration for deucravacitinib at Week 2Time frame: Week 2
  4. Proportion of subjects with at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) at Week 16Time frame: Week 16
  5. Proportion of subjects with an static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16Time frame: Week 16
  6. Incidence of Adverse Events (AEs)Time frame: Up to 316 weeks
  7. Incidence of serious adverse events (SAEs)Time frame: Up to 316 weeks
  8. Monitoring of growth: Body weightTime frame: Up to 316 weeks
  9. Monitoring of growth: HeightTime frame: Up to 316 weeks
  10. Monitoring of growth: Tanner staging (sexual maturation)Time frame: Up to 316 weeks

Locations

65 sites in 13 countries. Site status is shown where the registry gives one.

  • CONEXA Investigacion Clinica S.A.

    Buenos Aires, Argentina · Recruiting

  • Centro de Investigaciones Metabólicas (CINME)

    Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    CABA, Argentina · Recruiting

  • Consultora Integral de Salud

    Córdoba, Argentina · Recruiting

  • Instituto de Neumonologia Y Dermatologia

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Psoriahue

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Local Institution - 0020

    Darlinghurst, New South Wales, Australia · Active not recruiting

  • Local Institution - 0002

    Westmead, New South Wales, Australia · Withdrawn

  • Queensland Children's Hospital

    Brisbane, Queensland, Australia · Recruiting

  • Local Institution - 0003

    Woolloongabba, Queensland, Australia · Completed

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Local Institution - 0001

    Melbourne, Victoria, Australia · Completed

  • Local Institution - 0083

    Rio de Janeiro, Brazil · Withdrawn

  • Local Institution - 0067

    São Paulo, Brazil · Withdrawn

  • Centro de Pesquisas da Clínica IBIS

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) - HCFMRP

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Local Institution - 0010

    Calgary, Alberta, Canada · Completed

  • Alberta Dermasurgery Centre

    Edmonton, Alberta, Canada · Recruiting

  • Local Institution - 0039

    Hamilton, Ontario, Canada · Withdrawn

  • Lynderm Research Inc.

    Markham, Ontario, Canada · Recruiting

  • The Hospital for Sick Children

    Toronto, Ontario, Canada · Recruiting

  • Centre Hospitalier de Calais

    Calais, France · Recruiting

  • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand-dermatology

    Dijon, France · Recruiting

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet

    Nice, France · Recruiting

  • Local Institution - 0021

    Paris, France · Completed

  • Charité - Universitaetsmedizin Berlin - Campus Bejnamin Franklin

    Berlin, Germany · Recruiting

  • Kath. Kinderkrankenhaus Wilhelmstift

    Hamburg, Germany · Recruiting

  • Universitätsklinikum Münster

    Münster, North Rhine-Westphalia, Germany · Recruiting

  • Universitätsmedizin Johannes Gutenberg Universität Mainz

    Mainz, Rhineland-Palatinate, Germany · Recruiting

  • Universitaetsklinikum Carl Gustav Carus Dresden

    Dresden, Saxony, Germany · Recruiting

  • Nippon Life Hospital

    Osaka, Japan · Recruiting

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan · Recruiting

  • Fukuoka University Hospital

    Fukuoka, Jonan-Ku, Fukuoka, Japan · Recruiting

  • Local Institution - 0040

    Isehara, Kanagawa, Japan · Withdrawn

  • Mie University Hospital

    Tsu, Mie-ken, Japan · Recruiting

  • Tokyo Medical University Hospital

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Teikyo University Hospital

    tabashi City, Tokyo, Japan · Recruiting

  • Arké SMO S.A de C.V

    Veracruz, Mexico · Recruiting

  • Crea de Guadalajara

    Guadalajara, Jalisco, Mexico · Recruiting

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.